Edgestream Partners L.P. acquired a new position in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 86,512 shares of the biopharmaceutical company’s stock, valued at approximately $5,049,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in RPRX. Provenance Wealth Advisors LLC acquired a new stake in Royalty Pharma in the third quarter worth about $26,000. CoreCap Advisors LLC boosted its stake in Royalty Pharma by 89.2% during the 2nd quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 413 shares during the last quarter. Root Financial Partners LLC acquired a new position in Royalty Pharma during the third quarter valued at approximately $62,000. Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. bought a new stake in Royalty Pharma in the third quarter valued at approximately $63,000. Finally, Bessemer Group Inc. boosted its position in shares of Royalty Pharma by 34.7% during the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 282 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Royalty Pharma
In other news, EVP Christopher Hite sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $68.15, for a total transaction of $6,815,000.00. Following the completion of the sale, the executive vice president owned 177,523 shares in the company, valued at $12,098,192.45. The trade was a 36.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $57.10, for a total value of $235,594.60. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 440,788 shares of company stock valued at $29,157,162 in the last quarter. 18.84% of the stock is currently owned by insiders.
Analyst Ratings Changes
Several analysts recently commented on RPRX shares. Zacks Research raised Royalty Pharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 11th. Morgan Stanley raised their price objective on shares of Royalty Pharma from $65.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 14th. JPMorgan Chase & Co. lifted their price target on Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, TD Cowen lifted their target price on Royalty Pharma from $68.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $65.00.
Read Our Latest Analysis on Royalty Pharma
Royalty Pharma Stock Performance
Shares of RPRX stock opened at $68.67 on Thursday. The company has a fifty day moving average price of $61.93 and a two-hundred day moving average price of $54.95. Royalty Pharma PLC has a one year low of $37.31 and a one year high of $70.37. The stock has a market cap of $39.39 billion, a P/E ratio of 57.23, a P/E/G ratio of 1.36 and a beta of 0.37. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.29 and a quick ratio of 1.29.
Royalty Pharma Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a dividend of $0.2350 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.94 annualized dividend and a yield of 1.4%. Royalty Pharma’s dividend payout ratio (DPR) is currently 78.33%.
Royalty Pharma Company Profile
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Recommended Stories
- Five stocks we like better than Royalty Pharma
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX – Free Report).
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
